<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82139">
  <stage>Registered</stage>
  <submitdate>5/07/2007</submitdate>
  <approvaldate>9/07/2007</approvaldate>
  <actrnumber>ACTRN12607000364471</actrnumber>
  <trial_identification>
    <studytitle>Studies of Vitamin D supplements on Calcium Metabolism in Sarcoidosis</studytitle>
    <scientifictitle>A one year randomised, double-blind placebo-controlled trial to evaluate the effects of vitamin D supplementation on serum calcium, urine calcium, bone turnover and bone density in subjects with sarcoidosis and vitamin D insufficiency.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sarcoidosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Weekly oral calciferol 50,000 International Units (IU) for four weeks, then monthly oral calciferol 50,000 International Units (IU) for 11 months.</interventions>
    <comparator>Weekly oral placebo for four weeks, then monthly oral placebo for 11 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The difference in the change in serum calcium over 12 months between the two treatment groups.</outcome>
      <timepoint> Serum calcium will be measured at baseline, at weeks 2, 4, 6, 8, 12 and 16, and at months 6, 9, and 12.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between changes in urine calcium at the spine, proximal femur, and total body over 12 months between the two groups.</outcome>
      <timepoint>Measured at baseline, at weeks 4 and 16, and at 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between changes in bone turnover markers at the spine, proximal femur, and total body over 12 months between the two groups.</outcome>
      <timepoint>Measured at baseline, at weeks 4 and 16, and at 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between changes in bone density at the spine, proximal femur, and total body over 12 months between the two groups.</outcome>
      <timepoint>Measured at baseline and at months 6 and 12.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of sarcoidosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Serum creatinine &gt;0.15 mmol/L, nephrocalcinosis, hypercalcaemia (adjusted serum calcium &gt;2.55 mmol/L), concurrent major systemic illness (except for sarcoidosis) including malignancy, established osteoporosis (Bone mineral density T score &lt; -2.5 and a fragility fracture)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject numbers allocated by personnel based in a different building and having no contact with study subjects</concealment>
    <sequence>Computer-generated random numbers in variable blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The people receiving the treatment (subjects), the people administering the treatment, and the people assessing the outcomes (assessors) will be blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate>4/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/12/2010</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Mark Bolland</primarysponsorname>
    <primarysponsoraddress>Bone and Joint Research Group,
Department of Medicine,
University of Auckland,
85 Park Road, Grafton
Private Bag 92019, 
Auckland, 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Greenlane Research and Educational Fund</fundingname>
      <fundingaddress>The Green Lane Research and Educational Fund Board
Department of Cardiology
Level 3, Auckland City Hospital
Private Bag 92024,
Auckland, 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland Bone Research Group</sponsorname>
      <sponsoraddress>Bone and Joint Research Group,
Department of Medicine,
University of Auckland,
85 Park Road, Grafton
Private Bag 92019, 
Auckland, 1142</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a one year study designed to test whether vitamin D supplementation is safe and efficacious for patients with sarcoidosis and low vitamin D levels</summary>
    <trialwebsite />
    <publication>Bolland MJ, Wilsher ML, Grey A, Horne AM, Fenwick S, Gamble GD, Reid IR. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013; 3:e003562.
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Auckland</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/05/2007</ethicapprovaldate>
      <hrec>NTX/07/03/023</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Mark Bolland</name>
      <address>Bone Research Group
Department of Medicine
Auckland University
85 Park Rd
Grafton
Private Bag 92 019
Auckland 1020</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737677</fax>
      <email>m.bolland@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Diana Wattie</name>
      <address>Bone Research Group
Department of Medicine
Auckland University
85 Park Rd
Grafton
Private Bag 92 019
Auckland 1020</address>
      <phone>+64 9 3078970</phone>
      <fax>+64 9 3737677</fax>
      <email>d.wattie@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mark Bolland</name>
      <address>Bone Research Group Department of Medicine Auckland University 85 Park Rd Grafton Private Bag 92 019 Auckland 1020</address>
      <phone>6493737599</phone>
      <fax />
      <email>m.bolland@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>